Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC
Medical Sciences · 01.05.2026 · 14 (2) · 233
DOI: 10.3390/medsci14020233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, online erschienen am 01.05.2026. Verfasst von Abed Agbarya und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel. Hauptthemen laut MEDLINE: Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality despite major advances in diagnostics and therapies. The prognosis remains poor, mostly due to late-stage presentation and molecular heterogeneity. Epidermal growth factor receptor (EGFR) mutations are common drivers of NSCLC. The development of EGFR tyrosine kinase inhibitors (TKIs) has significantly improved outcomes in patients with EGFR mutations. Variant allele frequency (VAF) is a quantitative genomic measure representing the proportion of sequencing reads harboring a given mutation. In NSCLC tissue, the EGFR mutation VAF reflects tumor clonality and intratumoral heterogeneity, and accumulating evidence suggests an association between EGFR VAF and response to EGFR-targeted TKIs.
Methods
To address the limited synthesis of data on the relevance of EGFR mutation VAF in NSCLC, we conducted a narrative review of the literature using PubMed/MEDLINE and Embase databases and current clinical guidelines, synthesizing available evidence on EGFR VAF, including its biological, molecular, and therapeutic implications in EGFR-mutated disease. The review was structured in accordance with the SANRA (Scale for the Assessment of Narrative Review Articles) checklist.
Results
EGFR VAF and on-treatment VAF dynamics are consistently associated with treatment response, progression-free survival, and overall survival in osimertinib-treated NSCLC. Baseline VAF enables risk stratification, early clearance kinetics predict durable benefit, and longitudinal VAF monitoring facilitates early detection of resistance. Importantly, the prognostic implications of VAF differ fundamentally between tissue-based and plasma-based measurements: high tissue VAF reflects clonal homogeneity and predicts favorable TKI response, whereas high plasma VAF indicates elevated tumor burden and is associated with inferior outcomes. In the second-line setting, the T790M/activating mutation ratio serves as a surrogate for resistance clonality and independently predicts osimertinib efficacy.
Conclusions
EGFR VAF represents a promising dynamic molecular biomarker for treatment monitoring and precision decision-making in EGFR-mutated NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.
- Department of Oncology, Bnai-Zion Medical Center, Haifa 3339419, Israel.
- The Joseph Fishman Oncology Center, Rambam Medical Center, Haifa 3525409, Israel.
- Medical School for International Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 8410501, Israel.
- Faculty of Health Sciences, Ben Gurion University of the Negev, Ben Gurion Avenue, Beer Sheva 8410501, Israel.
- The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 8410501, Israel.
ORCID-Profile: Abed Agbarya, Mahmoud Abu Amna, Walid Shalata
Zitieren
APA
Agbarya, A., Mhameed, K., Soklakova, A., Nasrallah, H., Abu Amna, M., El-Saied, S., Sheikh-Ahmad, M., & Shalata, W. (2026). Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC. Medical Sciences, 14(2), 233. https://doi.org/10.3390/medsci14020233
Vancouver
Agbarya A, Mhameed K, Soklakova A, Nasrallah H, Abu Amna M, El-Saied S, et al. Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC. Medical Sciences. 2026;14(2):233. doi:10.3390/medsci14020233
BibTeX
@article{Agbarya2026,
author = {Agbarya, Abed and Mhameed, Kamel and Soklakova, Arina and Nasrallah, Haitam and Abu Amna, Mahmoud and El-Saied, Sabri and Sheikh-Ahmad, Mohammad and Shalata, Walid},
title = {Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {2},
pages = {233},
doi = {10.3390/medsci14020233}
}
EUVIMED